1 matory polyarthritis that persisted for up to 8 weeks after discontinuation of the study drug and was dose-limiting.

2 vely), resolution of fever (58 percent and 58 percent), and discontinuation of the study drug because of toxic effects or

3 ary end point was all-cause prophylaxis failure, defined as discontinuation of the study drug because of CMV antigen or D

4 ons, the data and safety monitoring board recommended early discontinuation of the study drug.

5 riods defined by the duration of study treatment, time from discontinuation of the study drug until disease progression,

6  10 (7%) placebo recipients had adverse events resulting in discontinuation of the study drug.

7  their serum creatinine (53% vs. 5%, P=0.001) necessitating discontinuation of the study drug.

8                                                 The rate of discontinuation of the study drug because of adverse events w

9                                                The rates of discontinuation of the study drug after randomization were si

10 serious adverse events, and there was no need for premature discontinuation of the study drug.

11 number of participants reporting adverse events that led to discontinuation of the study drug (36 [1%] of 2694 participan

12                                      Adverse effects led to discontinuation of the study drug in 19 patients assigned to